A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

References

• Werth V, Merrill J, Furie R, et al. OP0132 Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: results of a 24-week, placebo-controlled, Phase 2 study. Ann Rheum Dis. 2021;80(Suppl 1):76–77. doi:10.1136/annrheumdis-2021-eular.2181
   Google Scholar
• Thakurta A, Pierceall WE, Amatangelo MD, Flynt E, Agarwal A. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget. 2021;12(15):1555–1563. doi:10.18632/oncotarget.27973
   PubMedGoogle Scholar
• van de Donk NW, Popat R, Larsen J, et al. First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136(Supplement 1):16–17. doi:10.1182/blood-2020-137743
   Google Scholar
• Maples KT, Joseph NS, Harvey RD. Current developments in the combination therapy of relapsed/refractory multiple myeloma. Expert Rev Anticancer Ther. 2020;20(12):1021–1035. doi:10.1080/14737140.2020.1828071
   PubMed Web of Science ®Google Scholar
• Rivellese F, Manou-Stathopoulou S, Mauro D, et al. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Lupus Sci Med. 2021;8(1):e000445. doi:10.1136/lupus-2020-000445
   Web of Science ®Google Scholar
• Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197–1201. doi:10.1038/s41375-019-0620-8
   PubMed Web of Science ®Google Scholar
• Matyskiela ME, Zhang W, Man HW, et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018;61(2):535–542. doi:10.1021/acs.jmedchem.6b01921
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xue Y, Chen L, et al. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma. Br J Clin Pharmacol. 2022;2022:254.
   Google Scholar
• Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. Lancet Haematol. 2022;9:e822–e832.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Raab MS, Besemer B, et al. P-279: efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial. Clin Lymphoma Myeloma Leuk. 2022;22:S191–S192. doi:10.1016/S2152-2650(22)00609-7
   Web of Science ®Google Scholar
• Thieblemont C, Munoz J, Tucci A, et al. Iberdomide (CC-220) monotherapy or in combination with an anti-CD20 monoclonal antibody as effective therapy in patients with relapsed/refractory lymphoma: early results from a phase 1/2 study. Blood. 2022;140(Supplement 1):569–572. doi:10.1182/blood-2022-162559
   Google Scholar
• Amatangelo M, Cheng Y, Pierceall W, et al. P-231: biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial. Clin Lymphoma Myeloma Leuk. 2022;22:S162. doi:10.1016/S2152-2650(22)00561-4
   Web of Science ®Google Scholar
• Amatangelo M, Cheng Y, Pierceall W, et al. P865: biomarker analysis to support dose optimization of iberdomide as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial. Hemasphere. 2022;6(Suppl):758–759. doi:10.1097/01.HS9.0000846340.95760.ac
   Google Scholar
• Ye Y, Gaudy A, Schafer P, et al. First-in-human, single- and multiple-ascending-dose studies in healthy subjects to assess pharmacokinetics, pharmacodynamics, and safety/tolerability of iberdomide, a novel cereblon E3 ligase modulator. Clin Pharmacol Drug Dev. 2021;10(5):471–485. doi:10.1002/cpdd.869
   PubMed Web of Science ®Google Scholar
• Gaudy A, Atsriku C, Ye Y, et al. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects. Eur J Clin Pharmacol. 2021;77(2):223–231. doi:10.1007/s00228-020-03004-w
   Web of Science ®Google Scholar
• Cheng Y, Xue Y, Chen L, et al. Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma. Br J Clin Pharmacol. 2023;89(1):316–329. doi:10.1111/bcp.15498
   Web of Science ®Google Scholar
• Demirel S, Coskun F, Nak S, Ozyener F. Assessment of pulmonary functions with spirometry method in hepatic impairment patients. Ann Med Res. 2021;28(1):106–112.
   Google Scholar
• Manns MP, Burra P, Sargent J, Horton R, Karlsen TH. The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. Lancet. 2018;392(10148):621–622. doi:10.1016/S0140-6736(18)31734-3
   Web of Science ®Google Scholar
• FDA. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. FDA Guidance. FDA; 2003.
   Google Scholar
• Li Y, Wang X, Liu L, et al. An open-label, phase 1 study to assess the effects of hepatic impairment on pomalidomide pharmacokinetics. Clin Pharmacol Drug Dev. 2019;8(3):346–354. doi:10.1002/cpdd.470
   Web of Science ®Google Scholar
• EMA. Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Hepatic Function. EMA; 2005.
   Google Scholar